TY - JOUR
T1 - Estimating Time to ESRD in Children With CKD
AU - Chronic Kidney Disease in Children (CKiD)
AU - Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of CRF in Pediatric Patients (ESCAPE) Study Investigators
AU - Furth, Susan L.
AU - Pierce, Chris
AU - Hui, Wun Fung
AU - White, Colin A.
AU - Wong, Craig S.
AU - Schaefer, Franz
AU - Wühl, Elke
AU - Abraham, Alison G.
AU - Warady, Bradley A.
AU - Samuels, Joshua
AU - Furth, Susan
AU - Atkinson, Meredith
AU - Wilson, Amy
AU - Quiroga, Alejandro
AU - Massengill, Susan
AU - Selewski, Dave
AU - Ferris, Maria
AU - Kogon, Amy
AU - Kaskel, Frederick
AU - Lande, Marc
AU - Schwartz, George
AU - Saland, Jeffrey
AU - Norwood, Victoria
AU - Matoo, Tej
AU - Hidalgo, Guillermo
AU - Srivaths, Poyyapakkam
AU - Carlson, Joann
AU - Langman, Craig
AU - Mendley, Susan
AU - John, Eunice
AU - Upadhyay, Kiran
AU - Seo-Mayer, Patricia
AU - Patterson, Larry
AU - Parekh, Rulan
AU - Robinson, Lisa
AU - Weinstein, Adam
AU - Samsonov, Dmitry
AU - Kupferman, Juan
AU - Misurac, Jason
AU - Mongia, Anil
AU - Kiessling, Steffan
AU - Sanchez-Kazi, Cheryl
AU - Dart, Allison
AU - Fathallah, Sahar
AU - Claes, Donna
AU - Mitsnefes, Mark
AU - Blydt-Hansen, Tom
AU - Warady, Bradley
AU - Greenbaum, Larry
AU - Flynn, Joseph
N1 - Publisher Copyright:
© 2018 National Kidney Foundation, Inc.
PY - 2018/6
Y1 - 2018/6
N2 - Rationale & Objective: The KDIGO (Kidney Disease: Improving Global Outcomes) guideline for chronic kidney disease (CKD) presented an international classification system that ranks patients’ risk for CKD progression. Few data for children informed guideline development. Study Design: Observational cohort study. Settings & Participants: Children aged 1 to 18 years enrolled in the North American Chronic Kidney Disease in Children (CKiD) cohort study and the European Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of CRF in Pediatric Patients (ESCAPE) trial. Predictor: Level of estimated glomerular filtration rate (eGFR) and proteinuria (urine protein-creatinine ratio [UPCR]) at study entry. Outcome: A composite event of renal replacement therapy, 50% reduction in eGFR, or eGFR < 15 mL/min/1.73 m2. eGFR was estimated using the CKiD-derived “bedside” equation. Analytical Approach: Accelerated failure time models of the composite outcome using a conventional generalized gamma distribution. Likelihood ratio statistics of nested models were used to amalgamate levels of similar risk. Results: Among 1,232 children, median age was 12 (IQR, 8-15) years, median eGFR was 47 (IQR, 33-62) mL/min/1.73 m2, 60% were males, and 13% had UPCRs > 2.0 mg/mg at study entry. 6 ordered stages with varying combinations of eGFR categories (60-89, 45-59, 30-44, and 15-29 mL/min/1.73 m2) and UPCR categories (<0.5, 0.5-2.0, and >2.0 mg/mg) described the risk continuum. Median times to event ranged from longer than 10 years for eGFRs of 45 to 90 mL/min/1.73 m2 and UPCRs < 0.5 mg/mg to 0.8 years for eGFRs of 15 to 30 mL/min/1.73 m2 and UPCRs > 2 mg/mg. Children with glomerular disease were estimated to have a 43% shorter time to event than children with nonglomerular disease. Cross-validation demonstrated risk patterns that were consistent across the 10 subsample validation models. Limitations: Observational study, used cross-validation rather than external validation. Conclusions: CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children.
AB - Rationale & Objective: The KDIGO (Kidney Disease: Improving Global Outcomes) guideline for chronic kidney disease (CKD) presented an international classification system that ranks patients’ risk for CKD progression. Few data for children informed guideline development. Study Design: Observational cohort study. Settings & Participants: Children aged 1 to 18 years enrolled in the North American Chronic Kidney Disease in Children (CKiD) cohort study and the European Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of CRF in Pediatric Patients (ESCAPE) trial. Predictor: Level of estimated glomerular filtration rate (eGFR) and proteinuria (urine protein-creatinine ratio [UPCR]) at study entry. Outcome: A composite event of renal replacement therapy, 50% reduction in eGFR, or eGFR < 15 mL/min/1.73 m2. eGFR was estimated using the CKiD-derived “bedside” equation. Analytical Approach: Accelerated failure time models of the composite outcome using a conventional generalized gamma distribution. Likelihood ratio statistics of nested models were used to amalgamate levels of similar risk. Results: Among 1,232 children, median age was 12 (IQR, 8-15) years, median eGFR was 47 (IQR, 33-62) mL/min/1.73 m2, 60% were males, and 13% had UPCRs > 2.0 mg/mg at study entry. 6 ordered stages with varying combinations of eGFR categories (60-89, 45-59, 30-44, and 15-29 mL/min/1.73 m2) and UPCR categories (<0.5, 0.5-2.0, and >2.0 mg/mg) described the risk continuum. Median times to event ranged from longer than 10 years for eGFRs of 45 to 90 mL/min/1.73 m2 and UPCRs < 0.5 mg/mg to 0.8 years for eGFRs of 15 to 30 mL/min/1.73 m2 and UPCRs > 2 mg/mg. Children with glomerular disease were estimated to have a 43% shorter time to event than children with nonglomerular disease. Cross-validation demonstrated risk patterns that were consistent across the 10 subsample validation models. Limitations: Observational study, used cross-validation rather than external validation. Conclusions: CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children.
KW - Pediatric
KW - children
KW - chronic kidney disease (CKD)
KW - disease progression
KW - disease staging
KW - end-stage renal disease (ESRD)
KW - estimated glomerular filtration rate (eGFR)
KW - proteinuria
KW - risk pattern
KW - urinary protein-creatinine ratio (UPCR)
UR - http://www.scopus.com/inward/record.url?scp=85045892828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045892828&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.12.011
DO - 10.1053/j.ajkd.2017.12.011
M3 - Article
C2 - 29653769
AN - SCOPUS:85045892828
SN - 0272-6386
VL - 71
SP - 783
EP - 792
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -